| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
47,759 |
43,987 |
$2.77M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
10,715 |
10,689 |
$718K |
| 99058 |
|
9,772 |
8,779 |
$604K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
11,258 |
10,187 |
$530K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,005 |
5,684 |
$411K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
5,532 |
5,526 |
$297K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
13,328 |
11,977 |
$224K |
| G2086 |
Office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month |
423 |
371 |
$62K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
646 |
646 |
$57K |
| 86328 |
|
1,617 |
1,521 |
$44K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
4,273 |
3,977 |
$31K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
546 |
501 |
$16K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,459 |
1,438 |
$11K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,227 |
1,183 |
$7K |
| 99201 |
|
168 |
168 |
$7K |
| 99490 |
Ccm add 20min |
157 |
157 |
$6K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
160 |
159 |
$6K |
| 81002 |
|
2,968 |
2,908 |
$5K |
| 73130 |
|
108 |
104 |
$2K |
| 73630 |
|
73 |
69 |
$1K |
| 73610 |
|
71 |
69 |
$1K |
| 87400 |
|
109 |
109 |
$668.98 |
| 73562 |
|
13 |
13 |
$169.19 |
| 87430 |
|
53 |
52 |
$154.33 |
| 71046 |
Radiologic examination, chest; 2 views |
13 |
13 |
$150.57 |
| S9083 |
Global fee urgent care centers |
546 |
508 |
$145.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
296 |
284 |
$120.53 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
13 |
13 |
$41.13 |
| J1094 |
Injection, dexamethasone acetate, 1 mg |
348 |
341 |
$16.10 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
22 |
16 |
$0.00 |